Literature DB >> 12061429

Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease.

Cem Evereklioglu1, Hamdi Er, Yusuf Türköz, Mustafa Cekmen.   

Abstract

AIM: Behçet's disease (BD) is asystemic immunoinflammatory disorder and the aetiopathogenesis is to be specified. Cytokines play a role in immune response and in many inflammatory diseases. The aim of this case-control study is to investigate serum pro-inflammatory cytokine tumour necrosis factor (TNF)-alpha, interleukin-1beta (IL-1beta), soluble IL-2 receptor (sIL-2R), IL-6, and chemokine IL-8 levels in patients with BD. We also determined the end product of lipid peroxidation (malondialdehyde (MDA)) in BD patients as an index for oxidative stress.
METHODS: A total of 37 patients (19 men, 18 women) with BD (active, n = 17; inactive, n = 20) and 20 age-matched and sex-matched healthy control subjects (11 men, nine women) included in this cross-sectional, blinded study. Serum TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels were determined by a spectrophotometer technique using the immulite chemiluminescent immunometric assay. Lipid peroxidation was evaluated by Wasowicz et aL The levels of cytokines and lipid peroxidation in the active period were compared with the inactive period of the disease. Results are expressed as mean +/- standard error.
RESULTS: IL-1beta levels were below the detection limits of the assay (< 5 pg/ml) in all samples. Mean levels of MDA (8.1+/-0.7 micromol/l), sIL-2R (800+/-38 U/ml), IL-6 (12.6+/-1.1 pg/ml), IL-8 (7.2+/-0.4 pg/ml), and TNF-alpha (7.9+/-0.5 pg/ml) in active BD patients were significantly higher than those in inactive patients (4.3+/-0.5 micromol/l, p < 0.01; 447+/-16 U/ml, p < 0.001; 8.3+/-0.6 pg/ml, p = 0.006; 5.3+/-0.1 pg/ml, p < 0.001; and 5.1 0.2 pg/ml, p < 0.001; respectively) or control subjects (2.1+/-0.2 micromol/l, p < 0.001; 446+/-20 U/ml, p < 0.001; 6.4+/-0.2 pg/ml, p < 0.001; 5.4+/-0.1 pg/ml, p < 0.001; and 4.7+/-0.1 pg/ml, p < 0.001, respectively). On the contrary, only the mean IL-6 level was significantly different between inactive BD and control subjects (p = 0.02). All acute phase reactants were significantly higher in active BD than in inactive period (for each, p < 0.01).
CONCLUSIONS: High levels of sIL-2R, IL-6, IL-8 and TNF-alpha indicate the activation of immune system in BD. Serum sIL-2R, IL-6, IL-8 and TNF-alpha seem to be related to disease activity. Increased lipid peroxidation suggests oxidative stress in BD and therefore tissue damage in such patients. Amelioration of clinical manifestations would be envisaged by targeting these cytokines, chemokines and lipid peroxidation with pharmacological agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12061429      PMCID: PMC1781647          DOI: 10.1080/09629350220131935

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  31 in total

1.  Increased nitric oxide production in patients with Behçet's disease: is it a new activity marker?

Authors:  Cem Evereklioglu; Yusuf Turkoz; Hamdi Er; H Serhat Inaloz; Emin Ozbek; Mustafa Cekmen
Journal:  J Am Acad Dermatol       Date:  2002-01       Impact factor: 11.527

2.  Increased corneal thickness in active Behçet's disease.

Authors:  C Evereklioglu; H Er
Journal:  Eur J Ophthalmol       Date:  2002 Jan-Feb       Impact factor: 2.597

3.  Audio-vestibular evaluation in patients with Behçet's syndrome.

Authors:  C Evereklioglu; Y Cokkeser; S Doganay; H Er; A Kizilay
Journal:  J Laryngol Otol       Date:  2001-09       Impact factor: 1.469

4.  Thoracic involvement in Behçet's disease and its correlation with multiple parameters.

Authors:  H Gunen; C Evereklioglu; F Kosar; H Er; O Kizkin
Journal:  Lung       Date:  2000       Impact factor: 2.584

5.  International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease.

Authors:  E Bloch-Michel; R B Nussenblatt
Journal:  Am J Ophthalmol       Date:  1987-02-15       Impact factor: 5.258

Review 6.  Interleukin-1 and the pathogenesis of the acute-phase response.

Authors:  C A Dinarello
Journal:  N Engl J Med       Date:  1984-11-29       Impact factor: 91.245

7.  Vascular endothelial function and oxidative stress mechanisms in patients with Behçet's syndrome.

Authors:  J C Chambers; D O Haskard; J S Kooner
Journal:  J Am Coll Cardiol       Date:  2001-02       Impact factor: 24.094

8.  Evaluation of an automated immunoassay method for cytokine measurement using the Immulite Immunoassay system.

Authors:  F Berthier; C Lambert; C Genin; J Bienvenu
Journal:  Clin Chem Lab Med       Date:  1999-05       Impact factor: 3.694

9.  Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition.

Authors:  J A Symons; N C Wood; F S Di Giovine; G W Duff
Journal:  J Immunol       Date:  1988-10-15       Impact factor: 5.422

10.  Behçet's syndrome: immune regulation, circulating immune complexes, neutrophil migration, and colchicine therapy.

Authors:  J L Jorizzo; R D Hudson; F C Schmalstieg; J C Daniels; P Apisarnthanarax; J C Henry; E B Gonzalez; Y Ichikawa; T Cavallo
Journal:  J Am Acad Dermatol       Date:  1984-02       Impact factor: 11.527

View more
  55 in total

1.  Use of prognostic nutritional index in the evaluation of disease activity in patients with Behçet's disease.

Authors:  Nuh Ataş; Hakan Babaoğlu; Ertuğrul Demirel; Bülent Çelik; Reyhan Bilici Salman; Hasan Satış; Hazan Karadeniz; Aslıhan Avanoğlu Güler; Seminur Haznedaroğlu; Berna Göker; Abdurrahman Tufan; Mehmet Akif Öztürk
Journal:  Eur J Rheumatol       Date:  2020-07-21

2.  Long-term efficacy of infliximab treatment and the predictors of treatment outcomes in patients with refractory uveitis associated with Behçet's disease.

Authors:  Sho Ueda; Mitsuteru Akahoshi; Atsunobu Takeda; Yasushi Inoue; Aya Omoto; Masahiro Ayano; Yasutaka Kimoto; Hiroki Mitoma; Yojiro Arinobu; Hiroaki Niiro; Hiroshi Tsukamoto; Takahiko Horiuchi; Shin-Ichi Hikita; Takako Fukuhara; Tatsuro Ishibashi; Koh-Hei Sonoda; Koichi Akashi
Journal:  Eur J Rheumatol       Date:  2018-03

3.  Assessment of aortic stiffness and ventricular diastolic functions in patients with Behçet's disease.

Authors:  S Ercan Tunc; Abdullah Dogan; Omer Gedikli; Cagatay Arslan; Mehmet Sahin
Journal:  Rheumatol Int       Date:  2005-02-23       Impact factor: 2.631

4.  5,10-Methylenetetrahydrofolate reductase C677T gene polymorphism in Behcet's patients with or without ocular involvement.

Authors:  Y Ozkul; C Evereklioglu; M Borlu; S Taheri; M Calis; M Dündar; O Ilhan
Journal:  Br J Ophthalmol       Date:  2005-12       Impact factor: 4.638

5.  Diagnostic dilemma between intestinal Behçet disease and inflammatory bowel disease with pyoderma gangrenosum.

Authors:  Cem Evereklioglu
Journal:  World J Gastroenterol       Date:  2006-09-21       Impact factor: 5.742

6.  Circulating neutrophils in Behçet disease is resistant for apoptotic cell death in the remission phase of uveitis.

Authors:  Keita Fujimori; Keiko Oh-i; Masaru Takeuchi; Naoyuki Yamakawa; Takaaki Hattori; Takeshi Kezuka; Hiroshi Keino; Jun Suzuki; Hiroshi Goto; Jun-ichi Sakai; Masahiko Usui
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-10       Impact factor: 3.117

Review 7.  Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review.

Authors:  Jurgen Sota; Donato Rigante; Giuseppe Lopalco; Bruno Frediani; Rossella Franceschini; Mauro Galeazzi; Florenzo Iannone; Gian Marco Tosi; Claudia Fabiani; Luca Cantarini
Journal:  Rheumatol Int       Date:  2017-07-27       Impact factor: 2.631

8.  Neurotological status in Behçet's disease and its ophthalmological correlates.

Authors:  Y A Bayazit; C Evereklioğlu; E Ozer; N Kirtak; N Bayazit; M Kanlikama; S Inalöz
Journal:  Postgrad Med J       Date:  2004-12       Impact factor: 2.401

9.  Effects of treatment on free radicals in patients with pulmonary tuberculosis in South Western Nigeria.

Authors:  Wasiu Olalekan Adebimpe; Ayodeji Oluwaseun Faremi; Sulaiman Adebayo Nassar
Journal:  Afr Health Sci       Date:  2015-12       Impact factor: 0.927

10.  Release of B cell-activating factor of the TNF family in bronchoalveolar lavage from Behçet's disease with pulmonary involvement.

Authors:  Agnès Hamzaoui; Hanene Chelbi; Fayçal Hai Sassi; Kamel Hamzaoui
Journal:  Oxid Med Cell Longev       Date:  2010 Mar-Apr       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.